0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Systemic Sclerosis Drug Market Research Report 2024
Published Date: January 2024
|
Report Code: QYRE-Auto-17V9992
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Systemic Sclerosis Drug Market Insights Forecast to 2028
BUY CHAPTERS

Global Systemic Sclerosis Drug Market Research Report 2024

Code: QYRE-Auto-17V9992
Report
January 2024
Pages:106
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Systemic Sclerosis Drug Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Systemic Sclerosis Drug Market

Systemic Sclerosis Drug Market

The global Systemic Sclerosis Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Systemic Sclerosis Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Systemic Sclerosis Drug.

Report Scope

The Systemic Sclerosis Drug market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Systemic Sclerosis Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Systemic Sclerosis Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Systemic Sclerosis Drug Market Report

Report Metric Details
Report Name Systemic Sclerosis Drug Market
CAGR 5%
Segment by Type
  • ARG-201
  • Belimumab
  • BL-1110
  • BOT-191
  • C-82
  • Others
Segment by Application
  • Hospital
  • Clinic
  • ASCs
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Allergan Plc, Angion Biomedica Corp., arGentis Pharmaceuticals, LLC, Bayer AG, BioLineRx, Ltd., BiOrion Technologies B.V., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Corbus pharmaceuticals, Inc., CSL Limited, Daval International Limited, Digna Biotech, S.L., F. Hoffmann-La Roche Ltd., Fibrocell Science, Inc., GenKyoTex S.A., GlaxoSmithKline Plc
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Systemic Sclerosis Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Systemic Sclerosis Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Systemic Sclerosis Drug Market report?

Ans: The main players in the Systemic Sclerosis Drug Market are Allergan Plc, Angion Biomedica Corp., arGentis Pharmaceuticals, LLC, Bayer AG, BioLineRx, Ltd., BiOrion Technologies B.V., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Corbus pharmaceuticals, Inc., CSL Limited, Daval International Limited, Digna Biotech, S.L., F. Hoffmann-La Roche Ltd., Fibrocell Science, Inc., GenKyoTex S.A., GlaxoSmithKline Plc

What are the Application segmentation covered in the Systemic Sclerosis Drug Market report?

Ans: The Applications covered in the Systemic Sclerosis Drug Market report are Hospital, Clinic, ASCs, Others

What are the Type segmentation covered in the Systemic Sclerosis Drug Market report?

Ans: The Types covered in the Systemic Sclerosis Drug Market report are ARG-201, Belimumab, BL-1110, BOT-191, C-82, Others

1 Systemic Sclerosis Drug Market Overview
1.1 Product Overview and Scope of Systemic Sclerosis Drug
1.2 Systemic Sclerosis Drug Segment by Type
1.2.1 Global Systemic Sclerosis Drug Market Value Comparison by Type (2024-2030)
1.2.2 ARG-201
1.2.3 Belimumab
1.2.4 BL-1110
1.2.5 BOT-191
1.2.6 C-82
1.2.7 Others
1.3 Systemic Sclerosis Drug Segment by Application
1.3.1 Global Systemic Sclerosis Drug Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 ASCs
1.3.5 Others
1.4 Global Systemic Sclerosis Drug Market Size Estimates and Forecasts
1.4.1 Global Systemic Sclerosis Drug Revenue 2019-2030
1.4.2 Global Systemic Sclerosis Drug Sales 2019-2030
1.4.3 Global Systemic Sclerosis Drug Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Systemic Sclerosis Drug Market Competition by Manufacturers
2.1 Global Systemic Sclerosis Drug Sales Market Share by Manufacturers (2019-2024)
2.2 Global Systemic Sclerosis Drug Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Systemic Sclerosis Drug Average Price by Manufacturers (2019-2024)
2.4 Global Systemic Sclerosis Drug Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Systemic Sclerosis Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Systemic Sclerosis Drug, Product Type & Application
2.7 Systemic Sclerosis Drug Market Competitive Situation and Trends
2.7.1 Systemic Sclerosis Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Systemic Sclerosis Drug Players Market Share by Revenue
2.7.3 Global Systemic Sclerosis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Systemic Sclerosis Drug Retrospective Market Scenario by Region
3.1 Global Systemic Sclerosis Drug Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Systemic Sclerosis Drug Global Systemic Sclerosis Drug Sales by Region: 2019-2030
3.2.1 Global Systemic Sclerosis Drug Sales by Region: 2019-2024
3.2.2 Global Systemic Sclerosis Drug Sales by Region: 2025-2030
3.3 Global Systemic Sclerosis Drug Global Systemic Sclerosis Drug Revenue by Region: 2019-2030
3.3.1 Global Systemic Sclerosis Drug Revenue by Region: 2019-2024
3.3.2 Global Systemic Sclerosis Drug Revenue by Region: 2025-2030
3.4 North America Systemic Sclerosis Drug Market Facts & Figures by Country
3.4.1 North America Systemic Sclerosis Drug Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Systemic Sclerosis Drug Sales by Country (2019-2030)
3.4.3 North America Systemic Sclerosis Drug Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Systemic Sclerosis Drug Market Facts & Figures by Country
3.5.1 Europe Systemic Sclerosis Drug Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Systemic Sclerosis Drug Sales by Country (2019-2030)
3.5.3 Europe Systemic Sclerosis Drug Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Systemic Sclerosis Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Systemic Sclerosis Drug Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Systemic Sclerosis Drug Sales by Country (2019-2030)
3.6.3 Asia Pacific Systemic Sclerosis Drug Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Systemic Sclerosis Drug Market Facts & Figures by Country
3.7.1 Latin America Systemic Sclerosis Drug Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Systemic Sclerosis Drug Sales by Country (2019-2030)
3.7.3 Latin America Systemic Sclerosis Drug Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Systemic Sclerosis Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Systemic Sclerosis Drug Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Systemic Sclerosis Drug Sales by Country (2019-2030)
3.8.3 Middle East and Africa Systemic Sclerosis Drug Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Systemic Sclerosis Drug Sales by Type (2019-2030)
4.1.1 Global Systemic Sclerosis Drug Sales by Type (2019-2024)
4.1.2 Global Systemic Sclerosis Drug Sales by Type (2025-2030)
4.1.3 Global Systemic Sclerosis Drug Sales Market Share by Type (2019-2030)
4.2 Global Systemic Sclerosis Drug Revenue by Type (2019-2030)
4.2.1 Global Systemic Sclerosis Drug Revenue by Type (2019-2024)
4.2.2 Global Systemic Sclerosis Drug Revenue by Type (2025-2030)
4.2.3 Global Systemic Sclerosis Drug Revenue Market Share by Type (2019-2030)
4.3 Global Systemic Sclerosis Drug Price by Type (2019-2030)
5 Segment by Application
5.1 Global Systemic Sclerosis Drug Sales by Application (2019-2030)
5.1.1 Global Systemic Sclerosis Drug Sales by Application (2019-2024)
5.1.2 Global Systemic Sclerosis Drug Sales by Application (2025-2030)
5.1.3 Global Systemic Sclerosis Drug Sales Market Share by Application (2019-2030)
5.2 Global Systemic Sclerosis Drug Revenue by Application (2019-2030)
5.2.1 Global Systemic Sclerosis Drug Revenue by Application (2019-2024)
5.2.2 Global Systemic Sclerosis Drug Revenue by Application (2025-2030)
5.2.3 Global Systemic Sclerosis Drug Revenue Market Share by Application (2019-2030)
5.3 Global Systemic Sclerosis Drug Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Allergan Plc
6.1.1 Allergan Plc Corporation Information
6.1.2 Allergan Plc Description and Business Overview
6.1.3 Allergan Plc Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Allergan Plc Systemic Sclerosis Drug Product Portfolio
6.1.5 Allergan Plc Recent Developments/Updates
6.2 Angion Biomedica Corp.
6.2.1 Angion Biomedica Corp. Corporation Information
6.2.2 Angion Biomedica Corp. Description and Business Overview
6.2.3 Angion Biomedica Corp. Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Angion Biomedica Corp. Systemic Sclerosis Drug Product Portfolio
6.2.5 Angion Biomedica Corp. Recent Developments/Updates
6.3 arGentis Pharmaceuticals, LLC
6.3.1 arGentis Pharmaceuticals, LLC Corporation Information
6.3.2 arGentis Pharmaceuticals, LLC Description and Business Overview
6.3.3 arGentis Pharmaceuticals, LLC Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2019-2024)
6.3.4 arGentis Pharmaceuticals, LLC Systemic Sclerosis Drug Product Portfolio
6.3.5 arGentis Pharmaceuticals, LLC Recent Developments/Updates
6.4 Bayer AG
6.4.1 Bayer AG Corporation Information
6.4.2 Bayer AG Description and Business Overview
6.4.3 Bayer AG Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Bayer AG Systemic Sclerosis Drug Product Portfolio
6.4.5 Bayer AG Recent Developments/Updates
6.5 BioLineRx, Ltd.
6.5.1 BioLineRx, Ltd. Corporation Information
6.5.2 BioLineRx, Ltd. Description and Business Overview
6.5.3 BioLineRx, Ltd. Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2019-2024)
6.5.4 BioLineRx, Ltd. Systemic Sclerosis Drug Product Portfolio
6.5.5 BioLineRx, Ltd. Recent Developments/Updates
6.6 BiOrion Technologies B.V.
6.6.1 BiOrion Technologies B.V. Corporation Information
6.6.2 BiOrion Technologies B.V. Description and Business Overview
6.6.3 BiOrion Technologies B.V. Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2019-2024)
6.6.4 BiOrion Technologies B.V. Systemic Sclerosis Drug Product Portfolio
6.6.5 BiOrion Technologies B.V. Recent Developments/Updates
6.7 Boehringer Ingelheim GmbH
6.6.1 Boehringer Ingelheim GmbH Corporation Information
6.6.2 Boehringer Ingelheim GmbH Description and Business Overview
6.6.3 Boehringer Ingelheim GmbH Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Boehringer Ingelheim GmbH Systemic Sclerosis Drug Product Portfolio
6.7.5 Boehringer Ingelheim GmbH Recent Developments/Updates
6.8 Bristol-Myers Squibb Company
6.8.1 Bristol-Myers Squibb Company Corporation Information
6.8.2 Bristol-Myers Squibb Company Description and Business Overview
6.8.3 Bristol-Myers Squibb Company Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Bristol-Myers Squibb Company Systemic Sclerosis Drug Product Portfolio
6.8.5 Bristol-Myers Squibb Company Recent Developments/Updates
6.9 Corbus pharmaceuticals, Inc.
6.9.1 Corbus pharmaceuticals, Inc. Corporation Information
6.9.2 Corbus pharmaceuticals, Inc. Description and Business Overview
6.9.3 Corbus pharmaceuticals, Inc. Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Corbus pharmaceuticals, Inc. Systemic Sclerosis Drug Product Portfolio
6.9.5 Corbus pharmaceuticals, Inc. Recent Developments/Updates
6.10 CSL Limited
6.10.1 CSL Limited Corporation Information
6.10.2 CSL Limited Description and Business Overview
6.10.3 CSL Limited Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2019-2024)
6.10.4 CSL Limited Systemic Sclerosis Drug Product Portfolio
6.10.5 CSL Limited Recent Developments/Updates
6.11 Daval International Limited
6.11.1 Daval International Limited Corporation Information
6.11.2 Daval International Limited Systemic Sclerosis Drug Description and Business Overview
6.11.3 Daval International Limited Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Daval International Limited Systemic Sclerosis Drug Product Portfolio
6.11.5 Daval International Limited Recent Developments/Updates
6.12 Digna Biotech, S.L.
6.12.1 Digna Biotech, S.L. Corporation Information
6.12.2 Digna Biotech, S.L. Systemic Sclerosis Drug Description and Business Overview
6.12.3 Digna Biotech, S.L. Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Digna Biotech, S.L. Systemic Sclerosis Drug Product Portfolio
6.12.5 Digna Biotech, S.L. Recent Developments/Updates
6.13 F. Hoffmann-La Roche Ltd.
6.13.1 F. Hoffmann-La Roche Ltd. Corporation Information
6.13.2 F. Hoffmann-La Roche Ltd. Systemic Sclerosis Drug Description and Business Overview
6.13.3 F. Hoffmann-La Roche Ltd. Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2019-2024)
6.13.4 F. Hoffmann-La Roche Ltd. Systemic Sclerosis Drug Product Portfolio
6.13.5 F. Hoffmann-La Roche Ltd. Recent Developments/Updates
6.14 Fibrocell Science, Inc.
6.14.1 Fibrocell Science, Inc. Corporation Information
6.14.2 Fibrocell Science, Inc. Systemic Sclerosis Drug Description and Business Overview
6.14.3 Fibrocell Science, Inc. Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Fibrocell Science, Inc. Systemic Sclerosis Drug Product Portfolio
6.14.5 Fibrocell Science, Inc. Recent Developments/Updates
6.15 GenKyoTex S.A.
6.15.1 GenKyoTex S.A. Corporation Information
6.15.2 GenKyoTex S.A. Systemic Sclerosis Drug Description and Business Overview
6.15.3 GenKyoTex S.A. Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2019-2024)
6.15.4 GenKyoTex S.A. Systemic Sclerosis Drug Product Portfolio
6.15.5 GenKyoTex S.A. Recent Developments/Updates
6.16 GlaxoSmithKline Plc
6.16.1 GlaxoSmithKline Plc Corporation Information
6.16.2 GlaxoSmithKline Plc Systemic Sclerosis Drug Description and Business Overview
6.16.3 GlaxoSmithKline Plc Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2019-2024)
6.16.4 GlaxoSmithKline Plc Systemic Sclerosis Drug Product Portfolio
6.16.5 GlaxoSmithKline Plc Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Systemic Sclerosis Drug Industry Chain Analysis
7.2 Systemic Sclerosis Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Systemic Sclerosis Drug Production Mode & Process
7.4 Systemic Sclerosis Drug Sales and Marketing
7.4.1 Systemic Sclerosis Drug Sales Channels
7.4.2 Systemic Sclerosis Drug Distributors
7.5 Systemic Sclerosis Drug Customers
8 Systemic Sclerosis Drug Market Dynamics
8.1 Systemic Sclerosis Drug Industry Trends
8.2 Systemic Sclerosis Drug Market Drivers
8.3 Systemic Sclerosis Drug Market Challenges
8.4 Systemic Sclerosis Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
    Table 1. Global Systemic Sclerosis Drug Market Value Comparison by Type (2024-2030) & (US$ Million)
    Table 2. Global Systemic Sclerosis Drug Market Value Comparison by Application (2024-2030) & (US$ Million)
    Table 3. Global Systemic Sclerosis Drug Market Competitive Situation by Manufacturers in 2023
    Table 4. Global Systemic Sclerosis Drug Sales (K Pcs) of Key Manufacturers (2019-2024)
    Table 5. Global Systemic Sclerosis Drug Sales Market Share by Manufacturers (2019-2024)
    Table 6. Global Systemic Sclerosis Drug Revenue (US$ Million) by Manufacturers (2019-2024)
    Table 7. Global Systemic Sclerosis Drug Revenue Share by Manufacturers (2019-2024)
    Table 8. Global Market Systemic Sclerosis Drug Average Price (USD/Pcs) of Key Manufacturers (2019-2024)
    Table 9. Global Key Players of Systemic Sclerosis Drug, Industry Ranking, 2022 VS 2023 VS 2024
    Table 10. Global Key Manufacturers of Systemic Sclerosis Drug, Manufacturing Sites & Headquarters
    Table 11. Global Key Manufacturers of Systemic Sclerosis Drug, Product Type & Application
    Table 12. Global Key Manufacturers of Systemic Sclerosis Drug, Date of Enter into This Industry
    Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Systemic Sclerosis Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Systemic Sclerosis Drug as of 2023)
    Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 16. Global Systemic Sclerosis Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 17. Global Systemic Sclerosis Drug Sales by Region (2019-2024) & (K Pcs)
    Table 18. Global Systemic Sclerosis Drug Sales Market Share by Region (2019-2024)
    Table 19. Global Systemic Sclerosis Drug Sales by Region (2025-2030) & (K Pcs)
    Table 20. Global Systemic Sclerosis Drug Sales Market Share by Region (2025-2030)
    Table 21. Global Systemic Sclerosis Drug Revenue by Region (2019-2024) & (US$ Million)
    Table 22. Global Systemic Sclerosis Drug Revenue Market Share by Region (2019-2024)
    Table 23. Global Systemic Sclerosis Drug Revenue by Region (2025-2030) & (US$ Million)
    Table 24. Global Systemic Sclerosis Drug Revenue Market Share by Region (2025-2030)
    Table 25. North America Systemic Sclerosis Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 26. North America Systemic Sclerosis Drug Sales by Country (2019-2024) & (K Pcs)
    Table 27. North America Systemic Sclerosis Drug Sales by Country (2025-2030) & (K Pcs)
    Table 28. North America Systemic Sclerosis Drug Revenue by Country (2019-2024) & (US$ Million)
    Table 29. North America Systemic Sclerosis Drug Revenue by Country (2025-2030) & (US$ Million)
    Table 30. Europe Systemic Sclerosis Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 31. Europe Systemic Sclerosis Drug Sales by Country (2019-2024) & (K Pcs)
    Table 32. Europe Systemic Sclerosis Drug Sales by Country (2025-2030) & (K Pcs)
    Table 33. Europe Systemic Sclerosis Drug Revenue by Country (2019-2024) & (US$ Million)
    Table 34. Europe Systemic Sclerosis Drug Revenue by Country (2025-2030) & (US$ Million)
    Table 35. Asia Pacific Systemic Sclerosis Drug Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 36. Asia Pacific Systemic Sclerosis Drug Sales by Region (2019-2024) & (K Pcs)
    Table 37. Asia Pacific Systemic Sclerosis Drug Sales by Region (2025-2030) & (K Pcs)
    Table 38. Asia Pacific Systemic Sclerosis Drug Revenue by Region (2019-2024) & (US$ Million)
    Table 39. Asia Pacific Systemic Sclerosis Drug Revenue by Region (2025-2030) & (US$ Million)
    Table 40. Latin America Systemic Sclerosis Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 41. Latin America Systemic Sclerosis Drug Sales by Country (2019-2024) & (K Pcs)
    Table 42. Latin America Systemic Sclerosis Drug Sales by Country (2025-2030) & (K Pcs)
    Table 43. Latin America Systemic Sclerosis Drug Revenue by Country (2019-2024) & (US$ Million)
    Table 44. Latin America Systemic Sclerosis Drug Revenue by Country (2025-2030) & (US$ Million)
    Table 45. Middle East & Africa Systemic Sclerosis Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 46. Middle East & Africa Systemic Sclerosis Drug Sales by Country (2019-2024) & (K Pcs)
    Table 47. Middle East & Africa Systemic Sclerosis Drug Sales by Country (2025-2030) & (K Pcs)
    Table 48. Middle East & Africa Systemic Sclerosis Drug Revenue by Country (2019-2024) & (US$ Million)
    Table 49. Middle East & Africa Systemic Sclerosis Drug Revenue by Country (2025-2030) & (US$ Million)
    Table 50. Global Systemic Sclerosis Drug Sales (K Pcs) by Type (2019-2024)
    Table 51. Global Systemic Sclerosis Drug Sales (K Pcs) by Type (2025-2030)
    Table 52. Global Systemic Sclerosis Drug Sales Market Share by Type (2019-2024)
    Table 53. Global Systemic Sclerosis Drug Sales Market Share by Type (2025-2030)
    Table 54. Global Systemic Sclerosis Drug Revenue (US$ Million) by Type (2019-2024)
    Table 55. Global Systemic Sclerosis Drug Revenue (US$ Million) by Type (2025-2030)
    Table 56. Global Systemic Sclerosis Drug Revenue Market Share by Type (2019-2024)
    Table 57. Global Systemic Sclerosis Drug Revenue Market Share by Type (2025-2030)
    Table 58. Global Systemic Sclerosis Drug Price (USD/Pcs) by Type (2019-2024)
    Table 59. Global Systemic Sclerosis Drug Price (USD/Pcs) by Type (2025-2030)
    Table 60. Global Systemic Sclerosis Drug Sales (K Pcs) by Application (2019-2024)
    Table 61. Global Systemic Sclerosis Drug Sales (K Pcs) by Application (2025-2030)
    Table 62. Global Systemic Sclerosis Drug Sales Market Share by Application (2019-2024)
    Table 63. Global Systemic Sclerosis Drug Sales Market Share by Application (2025-2030)
    Table 64. Global Systemic Sclerosis Drug Revenue (US$ Million) by Application (2019-2024)
    Table 65. Global Systemic Sclerosis Drug Revenue (US$ Million) by Application (2025-2030)
    Table 66. Global Systemic Sclerosis Drug Revenue Market Share by Application (2019-2024)
    Table 67. Global Systemic Sclerosis Drug Revenue Market Share by Application (2025-2030)
    Table 68. Global Systemic Sclerosis Drug Price (USD/Pcs) by Application (2019-2024)
    Table 69. Global Systemic Sclerosis Drug Price (USD/Pcs) by Application (2025-2030)
    Table 70. Allergan Plc Corporation Information
    Table 71. Allergan Plc Description and Business Overview
    Table 72. Allergan Plc Systemic Sclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
    Table 73. Allergan Plc Systemic Sclerosis Drug Product
    Table 74. Allergan Plc Recent Developments/Updates
    Table 75. Angion Biomedica Corp. Corporation Information
    Table 76. Angion Biomedica Corp. Description and Business Overview
    Table 77. Angion Biomedica Corp. Systemic Sclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
    Table 78. Angion Biomedica Corp. Systemic Sclerosis Drug Product
    Table 79. Angion Biomedica Corp. Recent Developments/Updates
    Table 80. arGentis Pharmaceuticals, LLC Corporation Information
    Table 81. arGentis Pharmaceuticals, LLC Description and Business Overview
    Table 82. arGentis Pharmaceuticals, LLC Systemic Sclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
    Table 83. arGentis Pharmaceuticals, LLC Systemic Sclerosis Drug Product
    Table 84. arGentis Pharmaceuticals, LLC Recent Developments/Updates
    Table 85. Bayer AG Corporation Information
    Table 86. Bayer AG Description and Business Overview
    Table 87. Bayer AG Systemic Sclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
    Table 88. Bayer AG Systemic Sclerosis Drug Product
    Table 89. Bayer AG Recent Developments/Updates
    Table 90. BioLineRx, Ltd. Corporation Information
    Table 91. BioLineRx, Ltd. Description and Business Overview
    Table 92. BioLineRx, Ltd. Systemic Sclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
    Table 93. BioLineRx, Ltd. Systemic Sclerosis Drug Product
    Table 94. BioLineRx, Ltd. Recent Developments/Updates
    Table 95. BiOrion Technologies B.V. Corporation Information
    Table 96. BiOrion Technologies B.V. Description and Business Overview
    Table 97. BiOrion Technologies B.V. Systemic Sclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
    Table 98. BiOrion Technologies B.V. Systemic Sclerosis Drug Product
    Table 99. BiOrion Technologies B.V. Recent Developments/Updates
    Table 100. Boehringer Ingelheim GmbH Corporation Information
    Table 101. Boehringer Ingelheim GmbH Description and Business Overview
    Table 102. Boehringer Ingelheim GmbH Systemic Sclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
    Table 103. Boehringer Ingelheim GmbH Systemic Sclerosis Drug Product
    Table 104. Boehringer Ingelheim GmbH Recent Developments/Updates
    Table 105. Bristol-Myers Squibb Company Corporation Information
    Table 106. Bristol-Myers Squibb Company Description and Business Overview
    Table 107. Bristol-Myers Squibb Company Systemic Sclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
    Table 108. Bristol-Myers Squibb Company Systemic Sclerosis Drug Product
    Table 109. Bristol-Myers Squibb Company Recent Developments/Updates
    Table 110. Corbus pharmaceuticals, Inc. Corporation Information
    Table 111. Corbus pharmaceuticals, Inc. Description and Business Overview
    Table 112. Corbus pharmaceuticals, Inc. Systemic Sclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
    Table 113. Corbus pharmaceuticals, Inc. Systemic Sclerosis Drug Product
    Table 114. Corbus pharmaceuticals, Inc. Recent Developments/Updates
    Table 115. CSL Limited Corporation Information
    Table 116. CSL Limited Description and Business Overview
    Table 117. CSL Limited Systemic Sclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
    Table 118. CSL Limited Systemic Sclerosis Drug Product
    Table 119. CSL Limited Recent Developments/Updates
    Table 120. Daval International Limited Corporation Information
    Table 121. Daval International Limited Description and Business Overview
    Table 122. Daval International Limited Systemic Sclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
    Table 123. Daval International Limited Systemic Sclerosis Drug Product
    Table 124. Daval International Limited Recent Developments/Updates
    Table 125. Digna Biotech, S.L. Corporation Information
    Table 126. Digna Biotech, S.L. Description and Business Overview
    Table 127. Digna Biotech, S.L. Systemic Sclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
    Table 128. Digna Biotech, S.L. Systemic Sclerosis Drug Product
    Table 129. Digna Biotech, S.L. Recent Developments/Updates
    Table 130. F. Hoffmann-La Roche Ltd. Corporation Information
    Table 131. F. Hoffmann-La Roche Ltd. Description and Business Overview
    Table 132. F. Hoffmann-La Roche Ltd. Systemic Sclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
    Table 133. F. Hoffmann-La Roche Ltd. Systemic Sclerosis Drug Product
    Table 134. F. Hoffmann-La Roche Ltd. Recent Developments/Updates
    Table 135. Fibrocell Science, Inc. Corporation Information
    Table 136. Fibrocell Science, Inc. Description and Business Overview
    Table 137. Fibrocell Science, Inc. Systemic Sclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
    Table 138. Fibrocell Science, Inc. Systemic Sclerosis Drug Product
    Table 139. Fibrocell Science, Inc. Recent Developments/Updates
    Table 140. GenKyoTex S.A. Corporation Information
    Table 141. GenKyoTex S.A. Description and Business Overview
    Table 142. GenKyoTex S.A. Systemic Sclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
    Table 143. GenKyoTex S.A. Systemic Sclerosis Drug Product
    Table 144. GenKyoTex S.A. Recent Developments/Updates
    Table 145. GlaxoSmithKline Plc Corporation Information
    Table 146. GlaxoSmithKline Plc Description and Business Overview
    Table 147. GlaxoSmithKline Plc Systemic Sclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
    Table 148. GlaxoSmithKline Plc Systemic Sclerosis Drug Product
    Table 149. GlaxoSmithKline Plc Recent Developments/Updates
    Table 150. Key Raw Materials Lists
    Table 151. Raw Materials Key Suppliers Lists
    Table 152. Systemic Sclerosis Drug Distributors List
    Table 153. Systemic Sclerosis Drug Customers List
    Table 154. Systemic Sclerosis Drug Market Trends
    Table 155. Systemic Sclerosis Drug Market Drivers
    Table 156. Systemic Sclerosis Drug Market Challenges
    Table 157. Systemic Sclerosis Drug Market Restraints
    Table 158. Research Programs/Design for This Report
    Table 159. Key Data Information from Secondary Sources
    Table 160. Key Data Information from Primary Sources
List of Figures
    Figure 1. Product Picture of Systemic Sclerosis Drug
    Figure 2. Global Systemic Sclerosis Drug Market Value Comparison by Type (2024-2030) & (US$ Million)
    Figure 3. Global Systemic Sclerosis Drug Market Share by Type in 2023 & 2030
    Figure 4. ARG-201 Product Picture
    Figure 5. Belimumab Product Picture
    Figure 6. BL-1110 Product Picture
    Figure 7. BOT-191 Product Picture
    Figure 8. C-82 Product Picture
    Figure 9. Others Product Picture
    Figure 10. Global Systemic Sclerosis Drug Market Value Comparison by Application (2024-2030) & (US$ Million)
    Figure 11. Global Systemic Sclerosis Drug Market Share by Application in 2023 & 2030
    Figure 12. Hospital
    Figure 13. Clinic
    Figure 14. ASCs
    Figure 15. Others
    Figure 16. Global Systemic Sclerosis Drug Revenue, (US$ Million), 2019 VS 2023 VS 2030
    Figure 17. Global Systemic Sclerosis Drug Market Size (2019-2030) & (US$ Million)
    Figure 18. Global Systemic Sclerosis Drug Sales (2019-2030) & (K Pcs)
    Figure 19. Global Systemic Sclerosis Drug Average Price (USD/Pcs) & (2019-2030)
    Figure 20. Systemic Sclerosis Drug Report Years Considered
    Figure 21. Systemic Sclerosis Drug Sales Share by Manufacturers in 2023
    Figure 22. Global Systemic Sclerosis Drug Revenue Share by Manufacturers in 2023
    Figure 23. The Global 5 and 10 Largest Systemic Sclerosis Drug Players: Market Share by Revenue in 2023
    Figure 24. Systemic Sclerosis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
    Figure 25. Global Systemic Sclerosis Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Figure 26. North America Systemic Sclerosis Drug Sales Market Share by Country (2019-2030)
    Figure 27. North America Systemic Sclerosis Drug Revenue Market Share by Country (2019-2030)
    Figure 28. U.S. Systemic Sclerosis Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 29. Canada Systemic Sclerosis Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 30. Europe Systemic Sclerosis Drug Sales Market Share by Country (2019-2030)
    Figure 31. Europe Systemic Sclerosis Drug Revenue Market Share by Country (2019-2030)
    Figure 32. Germany Systemic Sclerosis Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 33. France Systemic Sclerosis Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 34. U.K. Systemic Sclerosis Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 35. Italy Systemic Sclerosis Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 36. Russia Systemic Sclerosis Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 37. Asia Pacific Systemic Sclerosis Drug Sales Market Share by Region (2019-2030)
    Figure 38. Asia Pacific Systemic Sclerosis Drug Revenue Market Share by Region (2019-2030)
    Figure 39. China Systemic Sclerosis Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 40. Japan Systemic Sclerosis Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 41. South Korea Systemic Sclerosis Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 42. India Systemic Sclerosis Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 43. Australia Systemic Sclerosis Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 44. Taiwan Systemic Sclerosis Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 45. Indonesia Systemic Sclerosis Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 46. Thailand Systemic Sclerosis Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 47. Malaysia Systemic Sclerosis Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 48. Philippines Systemic Sclerosis Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 49. Latin America Systemic Sclerosis Drug Sales Market Share by Country (2019-2030)
    Figure 50. Latin America Systemic Sclerosis Drug Revenue Market Share by Country (2019-2030)
    Figure 51. Mexico Systemic Sclerosis Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 52. Brazil Systemic Sclerosis Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 53. Argentina Systemic Sclerosis Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 54. Middle East & Africa Systemic Sclerosis Drug Sales Market Share by Country (2019-2030)
    Figure 55. Middle East & Africa Systemic Sclerosis Drug Revenue Market Share by Country (2019-2030)
    Figure 56. Turkey Systemic Sclerosis Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 57. Saudi Arabia Systemic Sclerosis Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 58. U.A.E Systemic Sclerosis Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 59. Global Sales Market Share of Systemic Sclerosis Drug by Type (2019-2030)
    Figure 60. Global Revenue Market Share of Systemic Sclerosis Drug by Type (2019-2030)
    Figure 61. Global Systemic Sclerosis Drug Price (USD/Pcs) by Type (2019-2030)
    Figure 62. Global Sales Market Share of Systemic Sclerosis Drug by Application (2019-2030)
    Figure 63. Global Revenue Market Share of Systemic Sclerosis Drug by Application (2019-2030)
    Figure 64. Global Systemic Sclerosis Drug Price (USD/Pcs) by Application (2019-2030)
    Figure 65. Systemic Sclerosis Drug Value Chain
    Figure 66. Systemic Sclerosis Drug Production Process
    Figure 67. Channels of Distribution (Direct Vs Distribution)
    Figure 68. Distributors Profiles
    Figure 69. Bottom-up and Top-down Approaches for This Report
    Figure 70. Data Triangulation
    Figure 71. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Nano String

SIMILAR REPORTS